Arcturus Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 17.15 M

LB filings
2025.11.12 11:27
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 17.15 M, beating the estimate of USD 16.03 M.

EPS: As of FY2025 Q3, the actual value is USD -0.49, beating the estimate of USD -0.899.

EBIT: As of FY2025 Q3, the actual value is USD -19.75 M.

Segment Revenue

  • Collaboration Revenue: $14.2 million for the three months ended September 30, 2025, compared to $38.8 million for the same period in 2024. For the nine months ended September 30, 2025, collaboration revenue was $64.1 million, compared to $117.4 million for the same period in 2024.
  • Grant Revenue: $3.0 million for the three months ended September 30, 2025, compared to $2.9 million for the same period in 2024. For the nine months ended September 30, 2025, grant revenue was $10.7 million, compared to $12.2 million for the same period in 2024.

Operational Metrics

  • Net Loss: $13.4 million for the three months ended September 30, 2025, compared to $6.9 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was $36.7 million, compared to $50.9 million for the same period in 2024.
  • Research and Development Expenses: $23.3 million for the three months ended September 30, 2025, compared to $39.1 million for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $87.7 million, compared to $151.4 million for the same period in 2024.
  • General and Administrative Expenses: $10.4 million for the three months ended September 30, 2025, compared to $13.3 million for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $32.1 million, compared to $40.4 million for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: - $58.0 million for the nine months ended September 30, 2025, compared to - $59.5 million for the same period in 2024.
  • Net Cash Used in Investing Activities: - $0.3 million for the nine months ended September 30, 2025, compared to - $0.7 million for the same period in 2024.
  • Net Cash Provided by Financing Activities: $1.7 million for the nine months ended September 30, 2025, compared to $5.3 million for the same period in 2024.

Unique Metrics

  • Deferred Revenue: $11.0 million as of September 30, 2025, compared to $32.1 million as of December 31, 2024.
  • Accounts Receivable: $8.0 million as of September 30, 2025, compared to $4.0 million as of December 31, 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to continue the development of its LUNAR-COV19 and LUNAR-FLU vaccine candidates, advance its LUNAR-OTC and LUNAR-CF programs in clinical trials, and maintain its collaboration with CSL Seqirus and BARDA.
  • Non-Core Business: The company is exploring additional partnerships and funding arrangements to support its long-term plans and may seek additional capital through equity and/or debt financings.
  • Priority: The company aims to achieve regulatory approvals and subsequent sales of KOSTAIVE, execute on milestones within the CSL Collaboration Agreement, and identify and develop other successful mRNA drug and vaccine candidates.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer